Stockwinners Market Radar for July 15, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:57 EDT Kohl's Chief Technology and Supply Chain Officer, Paul Gaffney, to depart - On July 15, Kohl's announced that Paul Gaffney, the company's Chief Technology and Supply Chain Officer, will be departing the company effective August 1. On July 15, the company also announced that Siobhan Mc Feeney was being promoted to Chief Technology Officer effective immediately. Mc Feeney has been with the company since January 2020, most recently serving as EVP-Technology. Prior to joining the company, she served as Vice President, Innovation and Strategy, at Pivotal Software from 2014 to January 2020.

17:26 EDT Booz Allen awarded $171.77M Navy contract - Booz Allen was awarded a $171.77M cost-plus-fixed-fee, cost reimbursable, indefinite-delivery/indefinite-quantity contract. This contract provides technical, analytical, and managerial services to support the Naval Aviation Enterprise for strategic objectives and initiatives in support of its mission to sustain required current readiness and advance future warfighting capabilities. Work is expected to be completed in August 2027. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was competitively procured via an electronic request for proposal; one offer was received. The Commander is the contracting activity.

17:07 EDT Hub Group opens second headquarters building - Hub Group announced the grand opening for its second office building on its Oak Brook, Illinois headquarters campus. This second building doubles Hub Group's footprint at its suburban Chicago headquarters, collectively accommodating up to 1,500 employees.

16:46 EDT Team receives continued listing notice from NYSE - Team announced that on July 13, 2022 it received written notice from the New York Stock Exchange that the company is not in compliance with the continued listing standards set forth in Rule 802.01C of the NYSE Listed Company Manual that requires listed companies to maintain an average closing share price of at least $1.00 over a consecutive 30 trading-day period. The NYSE rules require the company to notify the NYSE, within 10 business days of receipt of the Notice, of its intent to cure this deficiency. The company has six months following the receipt of the Notice to cure the deficiency and regain compliance. TEAM can regain compliance at any time during the six-month cure period if, on the last trading day of any calendar month during the cure period, its common stock has a closing price of at least $1.00 and an average closing price of at least $1.00 over the 30 consecutive trading-day period ending on the last trading day of that month. The company will closely monitor the closing share price of its common stock and is considering all available options and intends to regain compliance with the NYSE listing standards by pursuing measures that are in the best interests of the company and its shareholders, including potentially through the consummation of a reverse stock split, subject to Board and shareholder approval.

16:32 EDT Planet Green Holdings enters share exchange agreement - Planet Green Holdings announced that on July 15, the company has entered into a Share Exchange Agreement with Xianning Xiangtian Energy Holdings Group Co. and the shareholder of the Target. Pursuant to the Share Exchange Agreement, the company will acquire 30% of outstanding equity interests of the Target. The Target is a company that holds LNG production facilities through its subsidiary, and owns other assets. Pursuant to the Share Exchange Agreement, the company will issue 12,000,000 shares of common stock of the company to the Sellers in exchange for the transfer of 30% of the equity interest of the Target. The transaction is subject to closing conditions that are customary for transactions of this type.

16:23 EDT SeaChange chairman Robert Pons resigns, Peter Aquino named chairman - According to a regulatory filing, on July 12, 2022, Robert Pons resigned as Chairman and as a member of the Board of Directors of SeaChange International, effective immediately. Pons' departure is not a result of any disagreement with the company relating to the company's operations, policies or practices, according to the filing. In connection with Pons' above resignation, on July 14, 2022, the Board appointed Peter Aquino, a current member of the Board and the company's President and Chief Executive Officer, as Chairman of the Board, in addition to remaining as the company's President and Chief Executive Officer, and Matthew Stecker, a current member of the Board, as Lead Independent Director of the Board.

16:17 EDT Tiziana Life Sciences announces resignation of CEO Dr. Kunwar Shailubhai - Tiziana Life Sciences announces that the Board of Directors has accepted the voluntary resignation of Dr. Kunwar Shailubhai as CEO, Chief Scientific Officer and Board director, effective as of August 1. Dr. Shailubhai resigned for personal reasons, and his resignation is not related to any disagreement with the company on any matter relating to the company's operations, policies or practices. The Board has appointed Gabriele Cerrone, Executive Chairman of Tiziana, as interim CEO to lead the company through this period of transition. The Board will begin a search for a permanent CEO and Chief Scientific Officer immediately.

16:10 EDT PS Business Parks holders approve takeover by Blackstone Real Estate affiliates - PS Business Parks, Inc. (PSB) announced that, at a Special Meeting of Stockholders held earlier today, PSB stockholders voted to approve the acquisition of PSB by affiliates of Blackstone Real Estate (BX). "I am pleased to see that our stockholders approved this transformative transaction, which will provide compelling value to our stockholders and positions the company for collective success" said Stephen W. Wilson, President and Chief Executive Officer of PSB. Subject to the satisfaction or waiver of all of the conditions to the closing of the transaction in the merger agreement, the transaction is expected to be completed on or around July 20, 2022. The final voting results will be reported in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission after certification by PSB's inspector of elections.

16:06 EDT Mesabi Trust raises distribution to 84c per unit from 9c - The Trustees of Mesabi Trust declared a distribution of 84c per Unit of Beneficial Interest payable on August 20, 2022 to Mesabi Trust Unitholders of record at the close of business on July 30, 2022. This compares to a distribution of 9c per Unit for the same period last year. The 75c per Unit increase in the current distribution, as compared to the distribution announced by the Trust at the same time last year, is primarily attributable to an increase in the total royalties received by the Trust in April 2022, as compared to the total royalties received by the Trust in April 2021.

15:29 EDT New Jersey reports June gaming revenue up 2.2% to $401.5M - Based upon filings with the Division of Gaming Enforcement, total gaming revenue reported by casinos, racetracks, and their partners was $401.5M for June, reflecting a 2.2% increase from $392.8M reported in June 2021. For year-to-date, total gaming revenue reported by casinos, racetracks, and their partners was $2.43B reflecting a 15.2% increase from $2.11B reported in the prior period. Sports wagering gross revenue reported by casinos, racetracks, and their partners was $39.2M for June, reflecting a 44.9% decrease when compared to $71.3M in the prior period. Sports wagering gross revenue reported by casinos, racetracks and their partners was $308.7M for the year-to-date, reflecting a 16.2% decline when compared to $368.3M for the prior period. For the month of June, internet gaming win reported by casinos and their partners was $133.1M, reflecting growth of 24.4% compared to $107.1M for the prior period. For the year-to-date period, internet gaming win reported by casinos and their partners was $814.5M, reflecting growth of 28.4% compared to $634.2M for the prior year-to-date period. Total casino win for the nine casino hotel properties was $229.1M for June, reflecting growth of 6.8% compared to $214.5M for June 2021. Year-to-date total casino win for the nine casino hotel properties was $1.31B, reflecting growth of 18% compared to $1.11B for the prior period. Publicly traded companies in the space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn National (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

14:33 EDT Vuzix receives initial volume waveguide order - Vuzix Corporation announced that the company has received a volume OEM purchase order for custom designed waveguides from a Fortune 50 US based software and hardware technology customer, which plans to use them in their own head mounted display product development program. These waveguides are being built by Vuzix to specifically match the customer's needs and specifications. This initial volume order is from one of many companies joining Vuzix growing OEM business. "This order for custom waveguides represents the tip of the iceberg for Vuzix OEM supply efforts in terms of the expected long-term industry demand we are seeing," said Paul Travers, President and Chief Executive Officer at Vuzix. "Vuzix has already demonstrated to key customers its ability to design and deliver a variety of state-of-the-art custom waveguides and to manufacture them in volume at competitive costs. To address the growing OEM supply business, Vuzix also has plans in place to significantly increase its waveguide production capacity over the next year and further still into the future."

13:40 EDT Sony's acquisition of Bungie closes - Sony's PlayStation unit said in a tweet, "The agreement to acquire Bungie has closed. So now we can officially say... welcome to the PlayStation family, @Bungie!" The Fly notes that Bungie is responsible for the "Destiny" franchise of games.Reference Link

13:14 EDT ISS formally recommends Spirit shareholders vote against Frontier transaction

13:01 EDT Baker Hughes reports U.S. rig count up 4 to 756 rigs

12:58 EDT GRRR Stock trading resumes

12:30 EDT State Street raises FY22 NII view to up 24%-27% from up 18%-20%

12:20 EDT State Street says raising prices across services

12:09 EDT American Express reports June net write-off rate 0.8% vs. 0.9% in prior month - Reports June 30 days past due U.S. Consumer Card Member loans as a percent of total 0.7% vs. 0.7% in prior month.

12:02 EDT LiveOne to spin-out PodcastOne as separate public company by year end - LiveOne announced its intention to spin-out its wholly owned subsidiary, PodcastOne, as a separate public company to be listed on a national exchange and its plan to dividend a portion of PodcastOne's common equity to LiveOne's more than 15,000 stockholders as of a future record date, anticipated to be completed by year-end, in each case subject to obtaining applicable approvals and consents and complying with applicable rules and regulations and public market trading and listing requirements. In connection with the anticipated spin-out, PodcastOne closed a private placement financing of convertible notes and warrants totaling approximately $8.1M prior to offering expenses, including $3M invested by LiveOne, whereby the terms of the financing value PodcastOne at a pre-money valuation of $60M. Acquired by LiveOne in 2020, PodcastOne has had more than 2.1 billion downloads a year since its acquisition, across the more than 350 weekly episodes it distributes, the company said. LiveOne's CEO, Robert Ellin, stated, "The goal of both our management team and board of directors is to maximize stockholder value. PodcastOne has been a tremendous addition to LiveOne since our acquisition in 2020, and we feel strongly that the market value of our stock dramatically undervalues the sum of our parts, which includes our PodcastOne subsidiary. Upon the successful completion of the spin out, we believe PodcastOne will be the only major pure play podcast company trading on a national exchange."

12:00 EDT Innovative Industrial Properties falls -12.8% - Innovative Industrial Properties is down -12.8%, or -$14.24 to $97.02.

12:00 EDT Pinterest rises 14.8% - Pinterest is up 14.8%, or $2.59 to $20.15.

12:00 EDT Vertical Aerospace rises 41.0% - Vertical Aerospace is up 41.0%, or $1.19 to $4.09.

11:46 EDT State Street intends to resume common share repurchase program in Q4 - Says new business wins were well-diversified across client segments and geographies. Says Q2 saw continued revenue momentum in Alternatives despite equity and fixed income market declines. Comments taken from Q2 earnings presentation slides.

11:23 EDT European Commission approves Kinpeygo for adults with primary IgAN - Calliditas Therapeutics announced that the European Commission has granted conditional marketing authorization for Kinpeygo for the treatment of primary immunoglobulin A nephropathy in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio greater than or equal to1.5 g/gram. Kinpeygo is an orphan medicinal product and the first and only approved treatment for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease Kinpeygo will be marketed in the European Economic Area exclusively by STADA Arzneimittel. The conditional marketing authorization applies in all 27 European Union Member States as well as Iceland, Norway and Liechtenstein. Calliditas will transfer the Marketing Authorization for Kinpeygo to its commercial partner STADA, who plans to launch Kinpeygo in the EEA in the second half of 2022.

11:08 EDT Citi CEO: Little data suggests U.S. is on verge of recession - Comments taken from Q2 earnings conference call.

10:50 EDT Wells Fargo to be 'prudent' about share buybacks

10:38 EDT ITHAX Acquisition Corporation (Units) trading resumes

10:33 EDT Zhong Yang Financial Group Ltd trading resumes

10:32 EDT Sandvik completes acquisition of Peterson Tool Company - Sandvik has completed the previously announced acquisition of the assets of US based company Peterson Tool Company. The product offering includes custom carbide form inserts for high-production turning and grooving applications, primarily within the general engineering and automotive segments. The company will be reported in the GWS Tool business unit in Walter, a division within the business area Sandvik Manufacturing and Machining Solutions. In 2021 the company had revenues of $9M and an EBITA margin neutral to Sandvik Manufacturing and Machining Solutions. Impact on Sandvik's earnings per share will be limited, yet slightly positive.

10:29 EDT Wells Fargo sees another step down in asset fees in Q3

10:15 EDT Citi to pause share repurchases on capital rules, CFO Mark Mason said earlier

10:11 EDT Citi sees 5%-6% growth in expenses in FY22, low single digit growth in revenue

10:08 EDT Citi 'considering a full range of possibilities' to exit Russia businesses - Citi is considering a full range of possibilities to exit our Russia consumer and commercial banking businesses, including portfolio sales. Its Russia exposure increased roughly $500M from last quarter, Citi said in slides being presented on its Q2 earnings conference call.

10:06 EDT Wells Fargo CEO: Credit card spending began to slow in May, June - Comments taken from Q2 earnings conference call.

10:00 EDT Innovative Industrial Properties falls -13.1% - Innovative Industrial Properties is down -13.1%, or -$14.57 to $96.69.

10:00 EDT Harsco falls -17.1% - Harsco is down -17.1%, or -99c to $4.81.

10:00 EDT Pinterest rises 17.4% - Pinterest is up 17.4%, or $3.06 to $20.61.

09:47 EDT ITHAX Acquisition Corporation (Class A Stock) trading resumes

09:47 EDT KE Holdings falls -7.4% - KE Holdings is down -7.4%, or -$1.05 to $13.08.

09:47 EDT Coupang rises 7.9% - Coupang is up 7.9%, or $1.12 to $15.37.

09:47 EDT Vertical Aerospace rises 21.4% - Vertical Aerospace is up 21.4%, or 62c to $3.52.

09:45 EDT UnitedHealth to eliminate out-of-pocket costs on several prescription drugs - UnitedHealthcare will eliminate out-of-pocket costs in standard fully insured group plans for certain preferred prescription drugs, including insulin and several drugs used to treat emergencies such as severe allergic reactions, hypoglycemia, opioid overdoses, and acute asthma attacks. This new standard offering will be available to group fully insured plans potentially as early as January 1, 2023, subject to any required regulatory approval. These actions are part of UnitedHealth Group's ongoing efforts to ensure people get the drugs they need and to make health care more affordable. In addition to insulin, four preferred emergency use medications will be included in the new standard offering and will also have a $0 cost share: Epinephrine - severe allergic reactions; Glucagon - hypoglycemia; Naloxone - opioid overdoses; Albuterol - acute asthma attacks.

09:40 EDT Maravai LifeSciences trading halted, volatility trading pause

09:32 EDT Nymox says business plans continuing to be developed, on track - Nymox Pharmaceutical Corporation announced an update to its shareholders regarding progress in the company business activities. The company said, "Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The company will provide regular and further specific details when there is upcoming material information available to share. In the meantime, ongoing initiatives are continuing and are being positively advanced." Dr. Paul Averback, President and CEO stated, "The Company is well funded and despite setbacks we have advanced our main projects. We expect to provide important further details this summer and also this fall in Q3 and Q4."

09:27 EDT Upland Software announces $115M equity investment from HGGC, affirms Q2 view - Yesterday morning, Upland Software "announced a $115less than strategic equity investment from HGGC, a leading private equity firm with over $6.8 billion of cumulative capital commitments. The HGGC investment, in the form of a new class of convertible preferred stock issued at a premium to Upland's current market price, provides incremental capital intended to capture the attractive M&A opportunity set that is expected to emerge as a result of the current macroeconomic environment. It also brings additional strategic and operational support as HGGC and Upland work together to strengthen the company's go-to-market capability to fully leverage the value of its enterprise customer base and strong product portfolio." The company also "reaffirmed its guidance for the second quarter ended June 30, 2022. Upland will report its full second quarter results on August 3, 2022."

09:18 EDT Wells Fargo sees 2022 NII 20% higher than FY21's level of $35.8B

09:15 EDT Wells Fargo expects to increase Q3 dividend to 30c per share - Wells Fargo said it expects to increase the 3Q22 common stock dividend to 30c per share from 25c per share, subject to approval by the Company's Board of Directors at its regularly scheduled meeting in July. Comments taken from Q2 earnings conference call presentation slides.

09:09 EDT Cann American partner Cannagram featured at California State Fair - Cann American announced the Company's strategic investment partner, Cannagram, will be featured at the California State Fair. The company said, "As an investment partner in Cannagram, the Company is confident the exposure at the California State Fair will add widespread exposure to Cannagram and by extension, increase Cann American revenue and shareholder value."

09:06 EDT FingerMotion launches mobile device protection products - FingerMotion announced the launch of the mobile device protection products by FingerMotion's subsidiary, Shanghai TengLian Jiujiu Information and Communication Technology. The distribution of these mobile device protection products has started via Chinese carriers as embedded, value-added features to their device, voice and data plans. The first province in China to launch is Henan with a mobile subscriber base of 90M people with phased rollouts planned for the remaining provinces in the coming months targeting 1.2B subscribers.

09:03 EDT LPL Financial hires Sappington as EVP, Banking, Lending Solutions - LPL Financial announced that Bill Sappington joined the firm as executive vice president, EVP, Banking and Lending Solutions. Sappington will lead the firm's banking and lending solutions, developing and executing a strategy to deliver an industry-leading offering to LPL's advisors and clients. He will report to Kabir Sethi, LPL managing director and Chief Product Officer. Sappington has more than 30 years of experience and most recently served as the head of wealth management and private banking for City National Bank.

09:02 EDT Borqs' Holu Hou Energy signed agreement for $20M to deliver renewable energy - Borqs Technologies announced that its majority owned solar energy storage systems subsidiary, Holu Hou Energy, has signed agreement with Honokea Villages to deliver a major renewable energy generation and storage system to Honokea's planned ecological sports training and Hawaiian Cultural facility in their "ahupua'a", or local community. The development will have Olympic calibre training facilities for surfing, sport climbing, kayaking, beach volleyball, and more, and will serve as tool to celebrate athletics in Hawaii. The renewable energy system will feature over 3 MW of PV generation and over 4 MWh of energy storage, enough to power 100% of the operations of the facility, and will be financed under a 20-year power purchase agreement, or PPA. The system provided by HHE will begin construction in 2023 and its value is estimated at nearly $20M. This project is included in the $49.8 million of Q2 2022 signed contracts announced earlier this month.

09:00 EDT EyePoint reports 'positive' 12-month data from Phase 1 trial of EYP-1901 - EyePoint Pharmaceuticals announced 12-month data from the Phase 1 "Durasert and Vorolanib in Ophthalmology" clinical trial evaluating EYP-1901, a sustained delivery anti-vascular endothelial growth factor therapy targeting wet age-related macular degeneration as a potential every six-month treatment. These data are being presented today at the American Society of Retina Specialists 2022 Annual Meeting by Rishi Singh, M.D., Staff Physician, Cleveland Clinic Florida, President - Cleveland Clinic Martin Hospitals. The final twelve-month data presented from the Phase 1 DAVIO clinical trial showed no reports of ocular SAEs or drug-related systemic SAEs. There were no reported events of vitreous floaters, endophthalmitis, retinal detachment, implant migration in the anterior chamber, retinal vasculitis, posterior segment inflammation, or retinal vascular occlusive events. Additionally, updated data from the twelve-month follow-up confirm stable best corrected visual acuity, stable central subfield thickness on optical coherence tomography, and an expected late increase in supplemental anti-VEGF therapy given the insert's expected drug depletion, with 35% of eyes supplement free up to twelve months versus 53% supplement free up to six months. Additionally, there continued to be positive treatment burden reduction of 74% at twelve months versus 79% at six-months. EyePoint anticipates that the first patient in the twelve-month, randomized, controlled Phase 2 clinical trial of EYP-1901 for wet AMD will be dosed in Q3 2022. "We are extremely pleased with the excellent safety and efficacy results from our Phase 1 DAVIO trial. There remains a significant opportunity for a safe and effective sustained delivery maintenance treatment in wet AMD, and the DAVIO trial demonstrates that EYP-1901 has the potential to maintain a majority of patients for up to six months with no supplemental anti-VEGF therapy," said Nancy Lurker, CEO of EyePoint Pharmaceuticals. "We look forward to beginning to dose patients in the Phase 2 DAVIO2 clinical trial for EYP-1901 in wet AMD and anticipate top line data in the second half of 2023."

08:46 EDT SG Blocks authorizes share repurchase program for up to 500,000 shares - SG Blocks announced that its board of directors has authorized a share repurchase program of up to 500,000 shares. SG Blocks had 12M common shares outstanding at March 31. At the closing stock price of $1.58 per share on July 13th, the repurchase program is valued at up to $790,000.

08:37 EDT DigiMax completes substantially all closing tasks for Spetz acquisition - Pursuant to the June 23, 2022, announcement of the signing of the Definitive Agreement, DigiMax is pleased to report that the companies have completed substantially all closing tasks and the closing is now subject to satisfactory receipt of audited statements from the Spetz auditors for December 31 2020 and 2021, restated under IFRS guidelines. During this period, Spetz is continuing to operate and grow its existing businesses in Israel, the UK and Australia and is working toward a North American launch before the end of this calendar year. A demonstration of their success was noted recently as Spetz achieved #2 ranking in the Lifestyle Category on Israel Google Play behind only Pinterest. This is a demonstration of how well the brand is known and received in the jurisdictions in which it operates. In addition to this, Spetz recently aligned their Israeli market with their global markets, UK and Australia, by launching their service provider app in both iOS and Android. After only a few weeks of its launch the app has reached a rating of 4.9 out of 5 in the Google Play Store in Israel, demonstrating the benefit of the Spetz app in growing the businesses of service providers. Further, Spetz has recently launched a new partnership with Trade Trak, a leader in technology solutions for all trade service industries providing software and technology solutions to help trades streamline their businesses and processes. Through this partnership, Spetz has developed an advanced integration between the systems to allow service providers to receive all job requests inside the Trade Trak platform to easily manage invoicing, job scheduling and more. This partnership will allow Spetz access to thousands of service providers across Australia in order to rapidly grow their own provider database.

08:35 EDT Adverum Biotechnologies presents new data from OPTIC study during ASRS - Adverum Biotechnologies announced new data from the OPTIC study treating wet age-related macular degeneration, wet AMD, during the American Society of Retina Specialists, ASRS, 2022 Annual Meeting. New data presented are as of February 24, 2022 and include best-corrected visual acuity and central subfield thickness maintenance, as well as reduction in CST fluctuation after a single, in-office intravitreal injection of ADVM-022, ixoberogene soroparvovec, in subjects requiring frequent anti-VEGF injections for their wet AMD. Data Highlights as of February 24, 2022: OPTIC trial participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous therapeutic aflibercept protein expression levels through three years following a single, in-office intravitreal injection of ADVM-022; Mean BCVA change from baseline to last visit was maintained or improved for two years post-treatment with ADVM-022 across both the 6x10^11 vg/ey and 2x10^11 vg/eye dose levels; Mean CST was reduced by 55.7 microm at the 6E11 dose and by 95.9 microm at the 2E11 doseand maintained for two years following treatment across both ADVM-022 dose levels; In the 2E11 dose in subjects with neutralizing antibodies titers less than1:125, subjects demonstrated a mean BCVA improvement of 5.2 letters for two years following treatment with ADVM-022; ADVM-022 was well tolerated, with no participants in the 2E11 dose group requiring any topical corticosteroids to treat inflammation at most recent follow-up; No evidence of correlation between baseline NAbs and occurrence of inflammation or other safety events has been observed. Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies said, "As we recently announced, we completed our IND amendment with the U.S. Food and Drug Administration, received European Medicines Agency PRIME designation, and are preparing to initiate the Phase 2 LUNA trial of Ixo-vec in wet AMD. The LUNA trial was designed after a detailed data review from all 55 participants treated to date with a single ADVM-022 injection. Four new enhanced prophylactic steroid regimens will be evaluated in LUNA with the aim of providing steroid coverage during the period of peak immunogenicity. Our goal is to enhance the safety profile of ADVM-022 while building upon the impressive efficacy profile we continue to see in the OPTIC trial. We plan to dose the first subjects in the third quarter of 2022 and anticipate preliminary data from LUNA throughout 2023 and look forward to providing more detail on the expected timeline once we can assess the pace of enrollment."

08:32 EDT Quoin Pharmaceuticals, Endo enter into exclusive distribution, supply agreement - Quoin Pharmaceuticals (QNRX) has entered into the License and Distribution Agreement and the Supply Agreement with Endo Ventures Limited, a subsidiary of Endo International (ENDP), for the development, registration, supply, commercialization and distribution of QRX003, Quoin's lead product for Netherton Syndrome, on an exclusive basis in Canada. Under the terms of the License and Distribution Agreement, Endo Ventures has the exclusive right, which was sublicensed to its affiliate, Paladin Labs, to commercialize QRX003 in Canada, upon the receipt of the regulatory approvals. Under the Supply Agreement, Quoin is obligated to manufacture and supply the product to Endo Ventures. Quoin CEO, Dr. Michael Myers, said, "We are delighted to be partnering with Paladin for QRX003 and gaining the opportunity of benefiting from the company's deep knowledge and experience of the Canadian market. Paladin is a highly respected provider of a large number of innovative brands that have a significant impact on the everyday health and wellbeing of millions of Canadians, and we believe they are the best partner for Quoin in this very important market."

08:22 EDT Teledyne acquires majority interest in Noiseless Acoustics, terms undisclosed - Teledyne announced that it has acquired a majority interest in Noiseless Acoustics. NL Acoustics, located in Helsinki, Finland, designs and manufactures acoustics imaging instruments and predictive maintenance solutions. Terms of the transaction were not disclosed.

08:18 EDT Centogene expects improvements in 2022 adjusted EBITDA vs. prior year - "With the completion of the financings earlier this year, CENTOGENE is operating from a stable financial position. We rolled out multiple initiatives to extend our cash runway by closely managing margins and corporate expenses. As a result, we are expecting to show improvements in our 2022 adj. EBITDA versus the prior year," added Miguel Coego, Chief Financial Officer of CENTOGENE.

08:14 EDT Zymeworks announces intention to become a Delaware corporation - Zymeworks announced its intention to become a Delaware corporation, subject to receipt of necessary shareholder, stock exchange, and court approvals. Zymeworks believes that becoming a Delaware corporation will enhance long-term value for shareholders, help reduce certain administrative costs and complexities related to its future operations, including future monetization and partnering opportunities for its R&D programs, and better position the company for future growth. The company also believes that becoming a Delaware corporation may provide greater opportunities to expand its institutional investor base and may enable New Zymeworks to be eligible for inclusion in certain leading indices, such as the Russell and S&P indices, providing opportunities to be more closely aligned with its peers in the biotechnology sector. Zymeworks anticipates that the Redomicile will conclude in Q4, pending necessary shareholder, stock exchange, and court approval. Once the Redomicile is complete, New Zymeworks will continue under the current Zymeworks name and brand, and will continue to maintain significant operations in both Canada and the United States. In addition, the company is currently planning to expand its operations to Europe and Asia. To effect the Redomicile, Zymeworks will conduct a share exchange, pursuant to which holders of Zymeworks' common shares will exchange their Zymeworks common shares for shares of common stock of New Zymeworks or, at their election with respect to all or a portion of their Zymeworks common shares and subject to applicable eligibility criteria and an overall cap, exchangeable shares in the capital of a newly formed indirect subsidiary of New Zymeworks. A special meeting of Zymeworks security holders will be held to approve the redomicile. The redomicile requires the affirmative vote of two-thirds of votes cast at the special meeting, as well as approvals by the NYSE and the Supreme Court of British Columbia.

08:10 EDT First Wave BioPharma announces private placement - First Wave BioPharma announced that it has entered into a securities purchase agreement with several institutional accredited investors for the issuance and sale of an aggregate of 150 shares of its Series D Convertible Preferred Stock, stated value $1,000 per share, 150 shares of its Series E Convertible Preferred Stock, stated value $1,000 per share, and Series D Warrants to purchase up to 2,000,000 shares of its common stock in a private placement for aggregate gross proceeds of approximately $300,000, before deducting placement agent fees and other offering expenses. The shares of Series D Convertible Preferred Stock are convertible into an aggregate of 1,000,000 shares of common stock of the Company and the shares of Series E Convertible Preferred Stock are convertible into an aggregate of 1,000,000 shares of common stock of the Company, in each case, at a conversion price of $0.15 per share. The Series D Warrants have an exercise price of $0.15 per share, are exercisable commencing upon the effectiveness of the Reverse Split described below, and will expire five years from the initial exercise date. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The closing of the offering is expected to occur on or about July 15, 2022, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.

08:07 EDT Aura Minerals releases 2021 sustainability report - Aura Minerals releases its 2021 Sustainability Report. The report underscores the Company's commitment to being an innovative, safe, responsible, and sustainable mining Company, and highlights initiatives planned across eight ESG Pillars. This is the second consecutive year that Aura has published its sustainability report in accordance with Global Reporting Initiative standards, which encompasses performance on economic, environmental, and social aspects. Highlights of the 2021 Sustainability Report include: Implementing the Action Plan for the Advancement of Women in Mining in Brazil, developed by Women in Mining, across all the countries in which it operates; Committing to the participation of at least 40% of women in recruitment and selection processes for administrative positions; Mapping Aura's greenhouse gas emissions; establishing a decarbonization plan with the goal of reducing GHG emissions by 5% from 2020 levels by 2023; offering 10,000 hours of training in Compliance, Ethics, and use of the whistle-blowing channel to employees. Rodrigo Barbosa, CEO of Aura, commented: "The Aura 360 concept involves our commitment to the ESG agenda. Aura is taking important steps towards consolidating our ESG strategy. While there is more progress ahead, I am very proud of the achievements we made toward our goal of becoming one of the most respected and admired companies on the sector."

08:05 EDT Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule - Fulcrum Therapeutics announced that the Company granted non-statutory stock options to new employees as inducement awards outside of the Company's 2019 Stock Incentive Plan. Fulcrum granted stock options to purchase an aggregate of 33,620 shares of the Company's common stock to five new employees. The awards were granted as of July 11, 2022, pursuant to the Company's 2022 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Fulcrum Therapeutics in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the options has an exercise price of $5.69 per share, the closing price per share of the Company's common stock as reported by Nasdaq on July 11, 2022. Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to such employee's continued service with the Company through the applicable vesting dates.

08:04 EDT Synthetic Biologics announces reverse stock split - Synthetic Biologics announced a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one share of common stock for every ten shares of common stock, effective as of 12:01 a.m. on July 25, 2022. The Company's common stock will begin trading on a split-adjusted basis when the market opens on July 25, 2022. The reverse stock split was authorized by the Company's Board of Directors on July 11, 2022. Pursuant to the laws of the State of Nevada, the Company's state of incorporation, the Company's Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company's common stock will continue to trade on the NYSE American under the stock ticker "SYN" but will trade under the new CUSIP number 87164U409. As a result of the reverse split, each ten pre-split shares of common stock outstanding will automatically combine into one new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from 158,437,840 shares to 15,843,784 shares. The reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American, the Company's current listing exchange.

07:37 EDT NexGen Energy announces CNSC acceptance of EIS submission - NexGen Energy announced that the Canadian Nuclear Safety Commission, or CNSC, announced their acceptance of the draft Environmental Impact Statement, or EIS, which the company completed submission of in June. The acceptance of the draft EIS for NexGen's 100% owned Rook I Project located in Saskatchewan's southwestern Athabasca Basin follows a 30-day period during which the CNSC conducted a conformance review of the draft EIS submission and confirmed no comments or conditions. Further, the acceptance marks the formal commencement of the 90-day period during which the CNSC will coordinate both the Federal technical and public review of the draft EIS.

07:32 EDT Endo, Quoin Pharmaceuticals partner on development of QRX003 in Canada - Endo International (ENDP) announced that its subsidiary Endo Ventures Limited has entered into agreements with Quoin Pharmaceuticals (QNRX) for the development, registration, supply, commercialization and distribution of QRX003 on an exclusive basis in Canada. If the product is approved, Paladin Labs, an operating company of Endo, will be responsible for all commercial activities in Canada. QRX003 is Quoin's lead product for Netherton syndrome. Netherton syndrome, a form of ichthyosis, is a rare hereditary skin disorder caused by a mutation in the SPINK5 gene that leads to severe skin barrier defects and recurring infections, as well as a pronounced predisposition to allergies, asthma and eczema. Patients also often suffer from severe dehydration, chronic skin inflammation and stunted growth. Paladin currently expects to launch the product in 2025 in Canada.

07:10 EDT Wells Fargo reports Q2 net interest income up 16%, noninterest income down 40% - Wells Fargo said: "Net interest income increased 16%, primarily due to the impact of higher interest rates, higher loan balances, lower mortgage-backed securities premium amortization, and a decrease in long-term debt. These benefits were partially offset by lower interest income from Paycheck Protection Program loans and loans purchased from securitization pools. Noninterest income decreased 40%, primarily driven by lower results in our affiliated venture capital and private equity businesses, including impairments driven by market conditions; a decline in mortgage banking income driven by lower originations and gain on sale margins, as well as lower gains from the re-securitization of loans purchased from securitization pools; the impact of divestitures; and lower investment banking fees. These decreases were partially offset by improved results in our Markets business. Noninterest expense decreased 3%. Personnel expense was down predominantly reflecting divestitures, lower revenue-related compensation, as well as the impact of efficiency initiatives. Non-personnel expense also decreased, reflecting divestitures and lower consultant spend, partially offset by higher operating losses primarily driven by an increase in litigation accruals and higher customer remediation expense predominantly for a variety of historical matters. Provision for credit losses in second quarter 2022 included a $235M increase in the allowance for credit losses due to loan growth. Net loan charge-offs remained low. Commercial net loan charge-offs as a percentage of average loans were 0.02% annualized, compared with a net recovery of (0.02)%. The consumer net loan charge-off rate was 0.33% annualized, down from 0.35%."

07:02 EDT Kamada announces resolution to the labor strike at facility in Israel - Kamada announced that the Company, the Employees' Union of Kamada's Beit Kama production facility in Israel, and the Histadrut - General Federation of Labor in Israel, signed a new collective agreement detailing the understandings reached between the parties. The agreement will be effective through the end of 2029, while certain economic terms may be renegotiated by the parties following the lapse of the first four years of the term of the agreement. The previously disclosed labor strike has ended, and the unionized employees have now returned to work at the Beit Kama production facility. The strike had no impact on the availability of the Company's commercial products. However, as previously indicated, the Company's second quarter financial results are expected to be negatively affected by a one-time loss associated with the effect of the work-stoppage at the Israeli plant.

06:53 EDT NovaBay reports record Avenova sales during Amazon.com's Prime Day - NovaBay Pharmaceuticals (NBY) announces record sales of Avenova-branded products during Amazon's Prime Day event. Sales of Avenova-branded products during the two-day event increased 27% over Prime Days 2021 and 48% over Prime Days 2020, and reached a new one-day all-time high since the product became available on Amazon.com (AMZN) in June 2019.

06:49 EDT U.S. Bancorp reports Q2 net interest margin 2.59% vs. 2.53% a year ago - Reports Q2: Return on average assets of 1.16% and return on average common equity of 15.3%, excluding merger and integration charges. Common Equity Tier 1 capital ratio of 9.7% and strong levels of liquidity.

06:26 EDT Sonim director buys $11.7M in common stock - In a regulatory filing, Sonim disclosed that its director Jeffrey Wang bought 13.9M shares of common stock on July 13th in a total transaction size of $11.7M.

06:20 EDT BlackRock CEO: I see more opportunities for BlackRock today than ever before - Laurence Fink, Chairman and CEO said: "The first half of 2022 brought an investment environment that we have not seen in decades. Investors are simultaneously navigating high inflation, rising rates and the worst start to the year for both stocks and bonds in half a century, with global equity and fixed income indexes down 20% and 10%, respectively. BlackRock generated net inflows of $90 billion in the second quarter demonstrating our ability, once again, to deliver industry-leading organic growth even in the most challenging of environments. Our connectivity with clients has never been stronger. Over the last twelve months, we've delivered over $460 billion of net inflows reflecting 5% organic base fee growth. I cannot think of a time when BlackRock's strategic focus has been more aligned with the needs of our clients than it is today. ETFs generated $52 billion of net inflows, led by fixed income net inflows of $31 billion. Active strategies continued to reflect demand for systematic equity, LifePath target-date solutions and alternatives, where we raised nearly $8 billion across commitments and net inflows. BlackRock's cash platform reached record AUM levels in the quarter, generating $21 billion of net inflows. And, we had record Aladdin client mandates in the first half of 2022. Over the course of BlackRock's 34-year history, we have experienced numerous periods of volatility and uncertainty, and BlackRock has always come through stronger. It is during periods like these that we differentiate ourselves even more with clients and further deepen those relationships. I see more opportunities for BlackRock today than ever before, and remain confident in our ability to deliver long-term growth for our clients, shareholders and employees."

06:04 EDT UTStarcom regains Nasdaq listing compliance - UTStarcom announced the company received a formal notice from Nasdaq that it has regained compliance with Listing Rule 5450(a)(1) as a result of the closing bid price of the company's common stock has been at $1.00 per share or greater for the last 10 consecutive business days.

06:02 EDT Vertical Aerospace secures pre-delivery payment from American Airlines - Vertical Aerospace (EVTL) announces that it has confirmed delivery slots and the commitment of associated pre-delivery payments with American Airlines (AAL). American has reserved delivery slots for the first 50 VX4 aircraft of its initial conditional pre-order of up to 250 aircraft, with an option for an additional 100, announced in June 2021. The parties will build upon their existing joint working group to collaborate on a framework to explore the future of advanced air mobility and prepare for the VX4's entry into service. The commitment to pay pre-delivery payments and confirmation of slot reservations for the first 50 aircraft is believed to be the first of its kind for a major airline in the eVTOL industry, and it marks a significant milestone in the partnership between American and Vertical. This announcement follows the recent news of a further 50 conditional pre-orders of the VX4 from FLYINGGROUP, establishing Molicel as its battery partner, and agreeing to concurrent certification with the European Union's Aviation Safety Agency and the UK's Civil Aviation Authority.

05:17 EDT Itau Corpbanca files material event notice with Chilean Commission - Itau Corpbanca announced that it filed a material event notice with the Chilean Commission for the Financial Market reporting that Itau Corpbanca, Itau Unibanco, CorpGroup Interhold SpA, Inversiones GASA Limitada and other related companies of CG Banking, executed on June 3 a mutual termination letter, to terminate, among other agreements, the amended and restated transaction agreement, dated as of January 20, 2017, effective as of the plan effective date. In addition, Itau Corpbanca has been informed that CorpGroup Interhold SpA, Inversiones Gasa Limitada, CG Banking, CorpGroup Holding Inversiones Limitada, SAGA, ITB Holding Brasil Participacoes Ltda and Itau Unibanco Holding, executed a mutual termination letter on July 14 to terminate the shareholders agreement, dated as of April 1, 2016, as well as certain share purchase agreements, executed on October 26, 2016, September 13, 2017, October 12, 2018 and September 10, 2020, in each case effective as of the plan effective date. As part of the implementation of the Plan, CG Banking transferred to a subsidiary of Itau Unibanco Holding S.A. - ITB Holding Brasil Participacoes Ltda. - a total of 94,077,808,763 shares of Itau Corpbanca. As a result, Itau Unibanco Holding S.A. and its affiliates hold as of today 65.62% of Itau Corpbanca's common shares.

05:11 EDT PetMed Express becomes exclusive fulfillment partner for Vetster - PetMed Express has become the exclusive fulfillment partner for Vetster, a veterinary telemedicine and pet-care marketplace. The partnership enables the fulfillment of prescription medications and over-the-counter products through PetMeds to Vetster customers across the United States. The fulfillment partnership is part of a previously announced agreement that makes PetMeds the e-commerce provider of prescription and over-the-counter medication for Vetster customers and makes Vetster the exclusive provider of virtual care telehealth and telemedicine services to PetMeds.

05:06 EDT NetEase partners with FFF, AFA as online media partner in China - NetEase announced that NetEase Media, the company's media platform, has partnered with the French Football Federation, or FFF, and the Argentine Football Association, or AFA, to serve as their exclusive online media partner in China and provide exciting interactive content about the teams for the 2022 World Cup. Under the terms of the agreements, NetEase Media will distribute content for the two football teams across media outlets in China during the World Cup. Among other activities, NetEase Media will invite players and coaches of the teams to analyze and forecast the progression of the tournament through video chats, as well as produce documentaries about players such as Lionel Messi. In addition, Chinese fans of both teams will get a closer look at their favorite football stars through interactive posts and discussions on NetEase's platforms.